J Gastric Cancer.  2022 Mar;22(1):47-55. 10.5230/jgc.2022.22.e2.

Bleeding After Gastric Endoscopic Submucosal Dissection Focused on Management of Xa Inhibitors

• Ono S
• Ieko M
• Tanaka I
• Shimoda Y
• Ono M
• Yamamoto K
• Sakamoto N

• KMID: 2535086
• DOI: http://doi.org/10.5230/jgc.2022.22.e2

Abstract

Purpose
The use of direct oral Xa inhibitors (DXaIs) to prevent venothrombotic events is increasing. However, gastrointestinal bleeding, including that related to endoscopic resection, is a concern. In this study, we evaluated bleeding and coagulation times during the perioperative period of gastric endoscopic submucosal dissection (ESD).
Materials and Methods
Patients who consecutively underwent gastric ESD from August 2016 to December 2018 were analyzed. Bleeding rates were compared among the 3 groups (antiplatelet, DXaIs, and control). DXaI administration was discontinued on the day of the procedure. Prothrombin time (PT), activated partial thromboplastin time, and the ratio of inhibited thrombin generation (RITG), which was based on dilute PT, were determined before and after ESD.
Results
During the study period, 265 gastric ESDs were performed in 239 patients, where 23 and 50 patients received DXaIs and antiplatelets, respectively. Delayed bleeding occurred in 17 patients (7.4%) and 21 lesions (7.1%). The bleeding rate in the DXaI group was significantly higher than that in the other groups (30.4%, P<0.01), and the adjusted odds ratio of bleeding was 5.7 (95% confidence interval, 1.4–23.7; P=0.016). In patients using DXaIs, there was a significant (P=0.046) difference in the median RITG between bleeding cases (18.6%) and non-bleeding cases (3.8%).
Conclusions
A one-day cessation of DXaIs was related to a high incidence of bleeding after gastric ESD, and monitoring of residual coagulation activity at trough levels might enable the predicted risk of delayed bleeding in patients using DXaIs.

Keyword

Gastric cancer; Endoscopic submucosal dissection; Factor Xa inhibitor; Hemorrhage